Korean J Dermatol.
2022 Aug;60(7):444-448.
Two Case Reports of Leukocytoclastic Vasculitis after ChAdOx1 nCoV-19 Vaccine
- Affiliations
-
- 1Department of Dermatology and Division of Allergy, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 2Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
Abstract
- Leukocytoclastic vasculitis after the BNT162b2 vaccine and ChAdOx1 nCoV-19 Corona Virus vaccine [recombinant] has been observed. Herein, we report two cases of leukocytoclastic vasculitis that developed after the ChAdOx1-S [recombinant] vaccination. A 61-year-old and a 52-year-old woman presented with pruritic purpuric macules and papules on both lower legs. The patients had been vaccinated with the ChAdOx1-S [recombinant] vaccine. The histopathological analyses were consistent with a diagnosis of leukocytoclastic vasculitis. They were treated with oral prednisolone and improved within 1 month of treatment. We assume that the rash had arisen from the deposition of spike protein at the skin tissue induced by the viral vector of the COVID-19 vaccine or hyperimmune responses by excipients present in vaccine preparations. To our knowledge, our cases would be the first Korean cases of leukocytoclastic vasculitis after the ChAdOx1-S [recombinant] vaccination.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Livedo reticularis following administration of ChAdOx1 nCoV-19 vaccine (AZD1222): a report of two cases
- A Case of Leukocytoclastic Vasculitis Following COVID-19 Vaccination
- Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines
- Immunoglobulin A Vasculitis Following ChadOx1 nCoV-19/ AZD1222 (AstraZeneca COVID-19 Vaccine) Vaccination
- Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience
